We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. For further information please read our cookie policy.
Sayin, B., Dereli, B., Senol, Y. C., Akmangit, I., Karaman, A., Daglioglu, E., & Belen, A. D.
The Evaluation of Low-Profile Surpass Evolve™ Flow Diverter for Endovascular Treatment of Distal Cerebral Artery Aneurysms: A Single-Center Experience
98%
Near complete-complete occlusion rate (OKM C-D) at 16.2 months
82%
Complete occlusion rate (OKM D) at 16.2 months
| Number of patients | 41 |
| Number of aneurysms | 52 |
| Major morbidity and mortality | 0% |
| In-stent stenosis (≥50%) | 0% |
Turkish Neurosurgery | 2023
Sayin, B., Dereli, B., Senol, Y. C., Akmangit, I., Karaman, A., Daglioglu, E., & Belen, A. D. (2023). The Evaluation of Low-Profile Surpass EvolveTM Flow Diverter for Endovascular Treatment of Distal Cerebral Artery Aneurysms: A Single-Center Experience. Turkish neurosurgery, 33(3), 477–487. https://doi.org/10.5137/1019-5149.JTN.42071-22.1
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Stryker, Surpass Evolve. All other trademarks are trademarks of their respective owners or holders.
Information contained herein for use outside the US only.
AP004695 v1.0